Northland Securities Issues Positive Forecast for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its target price increased by research analysts at Northland Securities from $365.00 to $550.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Northland Securities’ price target suggests a potential downside of 7.59% from the company’s previous close.

A number of other equities research analysts have also issued reports on the stock. Barclays increased their target price on shares of Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. JMP Securities increased their price objective on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research note on Thursday, October 31st. Needham & Company LLC boosted their target price on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Bank of America assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target on the stock. Finally, Craig Hallum boosted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $427.83.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $595.18 on Monday. The stock has a market capitalization of $44.98 billion, a price-to-earnings ratio of 153.79, a price-to-earnings-growth ratio of 15.15 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The business has a 50-day moving average of $423.98 and a 200 day moving average of $351.79. Axon Enterprise has a 12 month low of $216.73 and a 12 month high of $624.84.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the transaction, the director now owns 7,379 shares of the company’s stock, valued at $2,752,588.37. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now directly owns 7,379 shares in the company, valued at approximately $2,752,588.37. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Patrick W. Smith sold 70,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $362.21, for a total value of $25,354,700.00. Following the completion of the transaction, the chief executive officer now owns 2,945,366 shares in the company, valued at $1,066,841,018.86. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 369,172 shares of company stock valued at $136,270,842 in the last three months. 6.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Avantax Advisory Services Inc. boosted its holdings in shares of Axon Enterprise by 0.8% in the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after acquiring an additional 40 shares in the last quarter. Foundations Investment Advisors LLC acquired a new stake in Axon Enterprise in the third quarter valued at about $221,000. Sequoia Financial Advisors LLC boosted its holdings in Axon Enterprise by 4.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock valued at $690,000 after purchasing an additional 81 shares in the last quarter. Jag Capital Management LLC increased its position in Axon Enterprise by 9.7% during the 3rd quarter. Jag Capital Management LLC now owns 56,086 shares of the biotechnology company’s stock worth $22,412,000 after purchasing an additional 4,954 shares during the period. Finally, Zurich Insurance Group Ltd FI raised its stake in shares of Axon Enterprise by 1.9% during the 2nd quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock worth $60,324,000 after buying an additional 3,832 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.